Fotivda (Tivozanib) 0.89mg is an oral, highly selective VEGFR tyrosine‑kinase inhibitor developed for adults with advanced renal cell carcinoma. By blocking vascular endothelial growth factor receptors, it restricts tumor angiogenesis, helping slow tumor growth and disease progression. Designed for patients whose cancer has returned or not responded to previous systemic therapies, Tivozanib provides targeted efficacy with a once‑daily dosing strategy to support long‑term management.
$4,650.00
| Active Ingredient | Tivozanib |
|---|---|
| Indication | For adults with relapsed or refractory advanced renal cell carcinoma cases only |
| Origin | Germany |
| Packaging | 21 capsules |
| Storage Temperature | Controlled room temperature |
| Strength | 0,89mg |